In the hunt for modifiable COVID-19 risk factors, vitamin D has gained a lot of attention both in the media and within the scientific community \[[@CR1]\]. Proponents of such a link cite a few early studies that present circumstantial evidence. They are either ecological, at an individual level but unable to fully adjust for potential confounders, or they measured 25-hydroxyvitamin D (25(OH)D) concentration once patients were already hospitalised with COVID-19 which introduces reverse causation, as vitamin D is a negative acute phase reactant \[[@CR2]\].

Despite the sparse evidence on vitamin D in COVID-19 \[[@CR3]\], the UK government led an urgent review into whether there is any link. It concluded that "There is no evidence to support taking vitamin D supplements to specifically prevent or treat COVID-19" \[[@CR4]\]. By contrast, the Welsh COVID-19 risk assessment tool includes vitamin D supplementation as part of its recommendations \[[@CR5]\]. Furthermore, a recent review conducted by the Scientific Advisory Committee on Nutrition found insufficient evidence to support recommending vitamin D supplementation to prevent acute respiratory tract infections in the general UK population \[[@CR6]\].

We previously observed no evidence of an association between baseline serum 25(OH)D concentration and testing positive for SARS-CoV-2 in hospital in UK Biobank once potential confounders were adjusted for \[[@CR7]\]. Importantly, some of the variables that were associated with increased COVID-19 risk in our sample, for example lower socioeconomic status, being Black or South Asian, or being overweight or obese, are also associated with lower vitamin D. This suggests that the positive findings of other studies may in part be due to inadequate adjustment. Another recent study of UK Biobank data replicated this finding \[[@CR8]\], but it would be more informative to relate 25(OH)D concentration to COVID-19-related mortality.

In the current analysis, we therefore linked baseline serum 25(OH)D concentration in 341,484 UK Biobank participants with complete data on covariates to Death Register data. In the sample, 203 participants died due to COVID-19 infection. Deaths occurred between the 5th of March and 25th of April 2020. We explored whether serum 25(OH)D concentration as a continuous measurement, or vitamin D deficiency or insufficiency (defined as serum 25(OH)D \< 25 and \< 50 nmol/L, respectively), were associated with risk of COVID-19 death using Cox proportional hazards regression analysis.

Univariably, several covariates were associated with COVID-19 mortality and infection (Table [1](#Tab1){ref-type="table"}). Notably, black and South Asian ethnicity, obesity, and lower socioeconomic status are also associated with lower 25(OH)D concentration.Table 1Univariable association between baseline covariates and confirmed COVID-19 mortality, and confirmed inpatient COVID-19 infectionCOVID-19 mortalityInpatient COVID-19 infectionHR (95% CI)*p*IRR (95% CI)*p*Sex Female11 Male2.49 (1.85--3.35) \< 0.0011.50 (1.29--1.75) \< 0.001Self-reported ethnicity White11 Black7.44 (4.30--12.9) \< 0.0013.14 (2.17--4.53) \< 0.001 South Asian1.76 (0.65--4.74)0.2642.69 (1.87--3.89) \< 0.001Townsend deprivation quintile 111 21.05 (0.64--1.72)0.8551.04 (0.79--1.36)0.802 30.95 (0.57--1.58)0.8451.08 (0.82--1.42)0.584 41.47 (0.93--2.34)0.1011.37 (1.06--1.77)0.016 52.56 (1.67--3.91) \< 0.0012.23 (1.75--2.83) \< 0.001Household income \< £18,00011 £18 k-£30,9990.47 (0.33--0.67) \< 0.0010.62 (0.51--0.76) \< 0.001 £31 k-£51,9990.42 (0.29--0.60) \< 0.0010.55 (0.45--0.68) \< 0.001 £52 k-£100,0000.28 (0.18--0.44) \< 0.0010.44 (0.34--0.55) \< 0.001 \> £100,0000.14 (0.04--0.43)0.0010.36 (0.23--0.56) \< 0.001Overall health rating Excellent11 Good1.52 (0.94--2.43)0.0851.49 (1.15--1.93)0.003 Fair3.49 (2.14--5.68) \< 0.0012.46 (1.86--3.26) \< 0.001 Poor4.86 (2.59--9.12) \< 0.0014.97 (3.54--6.96) \< 0.001Long-standing illness, disability or infirmity No11 Yes2.80 (2.13--3.70) \< 0.0011.84 (1.58--2.15) \< 0.001Smoking status No11 Yes1.36 (0.91--2.02)0.1341.34 (1.07--1.69)0.013BMI category Normal weight11 Underweight1.86 (0.26--13.6)0.5391.38 (0.44--4.31)0.584 Overweight1.82 (1.23--2.67)0.0021.50 (1.23--1.83) \< 0.001 Obese3.13 (2.12--4.62) \< 0.0012.02 (1.64--2.49) \< 0.001Diabetes No11 Yes5.06 (3.59--7.13) \< 0.0012.49 (1.96--3.17) \< 0.001Current age (years)1.13 (1.11--1.16) \< 0.0011.01 (1.00--1.02)0.007 Baseline systolic blood pressure (mmHg)1.02 (1.02--1.03) \< 0.0011.00 (0.999--1.01)0.123 Baseline diastolic blood pressure (mmHg)1.01 (0.998--1.03)0.0991.01 (0.999--1.01)0.109*HR* hazard ratio, *CI* confidence interval, *IRR* incidence rate ratio

The COVID-19 mortality results followed the same pattern that we previously observed for COVID-19 infection \[[@CR7]\]. Lower 25(OH)D concentration and vitamin D deficiency were both associated with higher risk of COVID-19 death univariably, but not after adjustment for potential confounders (Table [2](#Tab2){ref-type="table"}). Multivariate models were adjusted for all measured confounders as detailed in the table legend. Vitamin D insufficiency was not associated with risk of COVID-19 death univariably or multivariably. Furthermore, we repeated our previous analysis of the association between 25(OH)D and confirmed COVID-19 infection with additional cases, using univariable and multivariable poisson regression of inpatient diagnosed infection. There were 656 confirmed inpatient COVID-19 cases. Again, 25(OH)D concentration and vitamin D deficiency were associated with COVID-19 infection univariably but not multivariably (Table [2](#Tab2){ref-type="table"}).Table 2Association between baseline serum 25(OH)D and confirmed COVID-19 mortality, and confirmed inpatient COVID-19 infectionCOVID-19 mortalityInpatient COVID-19 infectionUnivariableMultivariable\*UnivariableMultivariable\*HR (95% CI)*p* valueHR (95% CI)*p* valueIRR (95% CI)*p* valueIRR (95% CI)*p* value25(OH)D (per 10 nmol/L)0.92 (0.86--0.98)0.0160.98 (0.91--1.06)0.6960.93 (0.90--0.97) \< 0.0011.00 (0.96--1.05)0.888Vitamin D deficient (25(OH)D \< 25 nmol/L)1.61 (1.14--2.27)0.0071.21 (0.83--1.76)0.3111.56 (1.28--1.90) \< 0.0011.10 (0.88--1.37)0.404Vitamin D insufficient (25(OH)D \< 50 nmol/L)1.29 (0.97--1.72)0.0761.02 (0.75--1.38)0.9191.33 (1.14--1.56) \< 0.0011.06 (0.89--1.26)0.525Participants who died of COVID-19 had a median age at death of 76 years (interquartile range 71--78 years)*HR* hazard ratio, *CI* confidence interval, *IRR* incidence rate ratio\*Adjusted for age, sex, ethnicity, month of assessment, Townsend deprivation quintile, household income, BMI category, smoking status, diabetes, systolic blood pressure, diastolic blood pressure, self-reported health rating, and long-standing illness, disability or infirmity

The variables significantly associated with risk of COVID-19 mortality in multivariate analysis were age (HR 1.12; 95% CI 1.10--1.15; *p* \< 0.001 per year), male sex (HR 2.12; 95% CI 1.56--2.89; *p* \< 0.001), black ethnicity (HR 8.13; 95% CI 4.56--14.50; *p* \< 0.001), obesity (HR 1.68; 95% CI 1.11--2.56; *p* = 0.015 compared with normal weight), socioeconomic deprivation (highest Townsend deprivation quintile compared with lowest HR 1.96; 95% CI 1.24--3.09; *p* = 0.004), and diabetes (HR 1.96; 95% CI 1.34--2.86; *p* = 0.001). These findings are consistent with other studies, lending strong external validity.

The main limitation of using UK Biobank for this analysis is the \~ 10 year time period between baseline 25(OH)D measurement and COVID-19 infection. We examined the concordance rates of vitamin D deficiency in a subsample of 15,473 participants who had measurements taken both at baseline and at a follow-up visit (on average 4.3 years later). Concordance in this group was 84%.

If there is a causal link, vitamin D supplements would present an appealingly cheap low risk intervention. However, currently there is no evidence that supplements will reduce risk of COVID-19 infection \[[@CR4]\], or acute respiratory tract infections more generally \[[@CR6]\]. NHS guidelines already recommend that all UK residents take vitamin D supplements in the winter, and furthermore that certain groups who are more likely to be deficient (for example those with darker skin) take them throughout the year \[[@CR9]\]. We await the results of randomised controlled trials to determine whether there should be any change to these guidelines and consequently clinical practice. For now, recommendations for vitamin D supplementation to lessen COVID-19 risks appear premature and, although they may cause little harm, they could provide false reassurance leading to changes in behaviour that increase risk of infections.
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